Find Clinical Trials

Inclusion Criteria: * To be between the ages of 40-69, * Baseline left ventricular ejection fraction (LVEF) \>50%, * Absence of coronary artery disease and haemodynamically significant valvular heart disease, * Absence of carotid atherosclerotic plaques, * Volunteering to participate in the research, * At least 15 months after breast cancer surgery, * No problems in reading and/or understanding the scales and being able to co-operate with the tests. * Physically inactive (60 minutes of structured exercise per week \<). Exclusion Criteria: * Presence of active infection, * Presence of bilateral breast cancer, * History of surgical, neurological or orthopaedic problems that may affect upper extremity functionality other than breast cancer surgery, * Having a neurological disease or other clinical diagnosis that may affect cognitive status, * Left ventricular dysfunction and severe liver and kidney dysfunction before starting chemotherapy * Musculoskeletal and neurological disease that may affect exercise performance, symptomatic heart disease, previous lung surgery and malignant disease. * Presence of unstable hypertension or diabetes mellitus.

Inclusion Criteria: * Adults aged 18 to 70 years. * Hospitalized patients with a diagnosis of type 2 diabetes mellitus (T2DM), either newly diagnosed during admission or previously known but not previously treated with insulin. * Initiation of insulin therapy (basal, basal-plus, or basal-bolus regimen) during hospitalization, with planned continuation post-discharge. * Independent in basic activities of daily living. * Adequate cognitive and functional capacity to manage the required devices: insulin pen, glucometer, continuous glucose monitoring (CGM) sensor, and Insulclock® cap. Exclusion Criteria: * Dependence in basic activities of daily living. * Any medical condition or functional limitation precluding the use of the CGM or the Insulclock® system. * Pregnancy or intention to become pregnant. * Diagnosis of type 1 diabetes mellitus. * Patients undergoing dialysis.

Inclusion Criteria: * Chief complaint of suicidal ideation, suicide attempt, depression, and/or anxiety * discharged from inpatient care or from emergency department * men and women ages 18-27 Exclusion Criteria: * primary diagnosis of: substance use disorder, schizophrenia spectrum, intellectual development disorder, autism spectrum disorder (level II or III)

Inclusion Criteria: 1. adults (\>=20 years old), 2. Type 2 Diabetes with coronary arterial disease underwent angioplasty within 3 months with SGLT2 inhibitors - Exclusion Criteria: 1. age\<20 years old, 2. pregnant women, 3. eGFR\<30 ml/min/1.73m2, 4. received GLP-1 agonist in the recent 3 months -

Key Inclusion Criteria: * Adults who were prescribed and had one successful fill for zuranolone within 12 months following end of pregnancy for the treatment of PPD from June 2025 to May 2026 through CVS Specialty Pharmacy. * Currently reside in the United States. * Able to complete the questionnaires independently. Key Exclusion Criteria: * Prior fill of zuranolone or brexanolone in last 12 months. * Participants with 2 or more doses of zuranolone at the time of screening. * Current or history of bipolar disorder. * Failure to complete baseline surveys prior to 2nd dose of zuranolone. * Pregnancy that ended more than 12 months ago. Other protocol-defined Inclusion/Exclusion criteria may apply.

Inclusion Criteria: * Male and female ages between ages 18-60 years. * Ability to give written informed consent (age 18 or above). * Diagnosed with schizophrenia-spectrum disorder and Evaluation to Sign Consent (ESC) above 10. * Score of Calgary depression scale for schizophrenia (CDSS) ≥ 3. Exclusion Criteria: * Inability to sign informed consent. * Any major medical illnesses that may affect normal brain functioning. Examples of these conditions include, but are not limited to: stroke, repeated seizure, history of significant head trauma with cognitive sequela, CNS infection or tumor, other significant brain neurological conditions. * Significant alcohol or other drug use other than nicotine or marijuana dependence. * Inability to refrain from using alcohol and/or marijuana 24 hours or more prior to experiments. * Pregnancy, as classified by a woman of child-bearing potential who is not using a contraceptive and has missed a menstrual period; or by self-report; or by positive urine pregnancy test. * For MRI, inability to participate in the MRI scanning due to metallic devices or objects (cardiac pacemaker or neurostimulator, some artificial joints, metal pins, surgical clips or other implanted metal parts) or declining to get in the scanner. * Failed TMS safety questionnaire.

Inclusion Criteria: Subjects must meet all of the following criteria to be enrolled in this study: Age: 18 to 75 years old (inclusive), male or female. Asthma Diagnosis: Diagnosed with asthma for at least 1 year, and current disease status meets the diagnostic criteria of the 2024 GINA Guidelines (Global Initiative for Asthma). Additionally: Has received moderate-to-high dose inhaled corticosteroids (ICS) for at least 2 consecutive months prior to screening. Pre-bronchodilator FEV1 (forced expiratory volume in 1 second) at screening and baseline visits is ≤80% of predicted normal value. Asthma Control Questionnaire-5 (ACQ-5) score ≥1.5 at screening and baseline visits. Has experienced ≥1 severe asthma exacerbation within the 12 months prior to screening. Exclusion Criteria: * 1， Known hypersensitivity to the investigational product or its excipients. 2，Clinical diagnosis of chronic obstructive pulmonary disease (COPD) or other lung diseases potentially impairing lung function (e.g., idiopathic pulmonary fibrosis, pneumothorax, atelectasis, pulmonary fibrosis, bronchial dysplasia, etc.), as determined by the investigator., 3，Experienced a severe asthma exacerbation during the screening period or within 1 month prior to dosing., 4，Received systemic glucocorticoid therapy from 1 month prior to screening to prior to dosing (excluding topical, ophthalmic, or intranasal glucocorticoids). 5，Had pulmonary or other site infections requiring intravenous antibiotics, antifungal, or antiviral medications within 1 month prior to dosing. 6，Received intravenous immunoglobulin (IVIG) therapy or allergen-specific immunotherapy (SIT) within 3 months prior to dosing. 7，Used traditional Chinese herbal medicines with bronchodilatory or anti-asthmatic effects (excluding topical preparations) within 1 month prior to dosing. 8，Underwent major surgery within 8 weeks prior to screening or planned to undergo major surgery during the study period (including hospitalized surgery and day-case surgery).

Inclusion Criteria: * At least the age of 18 * Self identify as Black/African-American * Self-report current asthma diagnosis * Asthma must be persistent (Prescribed an inhaled corticosteroid (alone or in combination) * Asthma must be uncontrolled (≥1 exacerbation in the past years OR Asthma Control Questionnaire \> 0.75) * Have moderate-high stress (Perceived Stress Scale ≥ 14) * Presented at any Primary Care clinic in the past 3 years. Exclusion Criteria: * Unable or unwilling to give consent * Diagnosis of a psychotic disorder * Positive responses to questions regarding suicidality

Inclusion Criteria 1. Candidate for general anesthesia. 2. Age 18-70 years at consent. 3. BMI 35-70 kg/m² at first study visit. 4. Eligible for sleeve gastrectomy per ASMBS/IFSO 2022 guidelines. 5. Insurance coverage for metabolic surgery. 6. Current or prior anti-obesity medication use permitted. 7. Liver cirrhosis confirmed by biopsy or non-invasive assessment. 8. Clinically significant portal hypertension (HVPG ≥ 10 mm Hg, or esophagogastric varices / portal-hypertensive gastropathy, or imaging evidence of collaterals/dilated portal vein). 9. Able and willing to provide informed consent and comply with study procedures. 10. Women of child-bearing potential: negative urine pregnancy test at screening and randomization and agreement to reliable contraception for 2 years. Exclusion Criteria 1. Prior bariatric/metabolic surgery (except removed devices ≥ 3 months earlier). 2. Prior complex foregut surgery. 3. History of solid-organ transplant. 4. Severe pulmonary disease (FEV1 \< 50 % predicted). 5. Significant cardiac or atherosclerotic disease with planned re-vascularization within 12 months. 6. ASA class IV or V uncompensated cardiopulmonary disease. 7. Left-ventricular ejection fraction \< 25 % or MI/unstable angina/stroke/heart surgery/coronary stent within 6 months. 8. Hiatal hernia \> 7 cm or LA grade C/D erosive esophagitis. 9. Active Crohn's disease. 10. Severe psychiatric illness, dementia, active psychosis, history of suicide attempt, or alcohol/substance abuse within 12 months. 11. Pregnant, breastfeeding, planning pregnancy, or not using adequate contraception. 12. Malignancy within the prior 12 months (except non-melanoma skin cancer). 13. Life expectancy \< 2 years in investigator's judgment. 14. Investigational therapy within 3 months. 15. Acute pancreatitis ≤ 90 days. 16. Portal vein thrombosis at screening. 17. Decompensated cirrhosis (moderate/large ascites, hepatic encephalopathy, or listed for liver transplant); small ascites or prior variceal bleed allowed. 18. Total bilirubin \> 3 mg/dL, INR \> 1.7, or platelets \< 50 000/µL (within 1 month). 19. Significant alcohol intake (\> 14 units/week women, \> 21 units/week men) within the prior 12 months. 20. eGFR \< 45 mL/min/1.73 m² or on dialysis (within 1 month). 21. AIDS. 22. Unable to understand study or give consent. 23. Plans to move more than 3 hours from Cleveland within 6 months. 24. Previous randomization in this trial. 25. Any condition that, in the investigator's opinion, places the subject at undue risk.

Inclusion Criteria: * Meet the diagnostic criteria for depressive episodes of ICD-10; * Hamilton Depression Scale -17 items score ≥14 points; * The diagnosis should be confirmed by at least two physicians with the title of attending physician or above. * Have sufficient visual and auditory levels to ensure that the necessary checks and experiments for the research can be completed; * Sign the written informed consent form and agree to be enrolled in the trial as required by the research plan. Exclusion Criteria: * There are serious heart, liver and kidney diseases, organic brain diseases, serious cardiovascular diseases, tumors, blood history, rheumatism, malnutrition and neurodegenerative diseases, etc. * Depressive episodes secondary to other mental or physical illnesses; * There is a history of abuse of tobacco, alcohol and other psychoactive substances; * Those with comorbidities of other mental disorders; * Had participated in other drug clinical trials before inclusion.

Inclusion Criteria: * Must have a confirmed diagnosis of major depressive disorder (MDD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition at the time of enrollment, without psychotic features, based on clinical assessment, and confirmed by mini international neuropsychiatric interview (MINI) * Must have a Hamilton depression rating scale (HAM-D; 17-item) total score greater than or equal to (\>=) 22 at screening and Day 1 * Participants must have had non-response (less than or equal to \[\<=\] 25 percent \[%\] improvement of symptoms) to \>= 2 oral antidepressant treatments in the current moderate to severe episode of depression after having been given at an adequate dosage for an adequate duration of at least 6 weeks * At baseline (Day 1), the investigator will evaluate any changes in the participant's signs/symptoms of depression since the screening assessment and confirm that the inclusion criteria for the current antidepressant (AD) treatment are still met (that is, nonresponse and minimal clinical improvement) * A female participant of childbearing potential must have a negative serum pregnancy test at screening and urine prior to the first dose of study intervention on Day 1 Exclusion Criteria: * Participants with hyperthyroidism that has not been sufficiently treated * History of malignancy within 5 years of enrollment before screening * Known allergies, hypersensitivity, or intolerance to esketamine/ketamine or its excipients * Received an investigational intervention or used an invasive investigational medical device within 60 days before the planned first dose of study intervention or first data collection time point * Currently enrolled in an investigational study that involves treatments for MDD or may otherwise be expected to impact mood

Inclusion Criteria:Female patients with primary breast cancer * Patients with unilateral breast cancer * Those who had breast cancer surgery at least 1 month ago * Unilateral mastectomy with axillary lymph node dissection (removal of at least 2 lymph nodes) * 18 years of age or older * Patients with a body mass index (BMI) ≤ 30 (pretreatment BMI may be a risk factor for lymphedema) * Those who have a smartphone and know how to use it * Those without a defined severe mental disorder * Those who can speak Turkish and have the ability to read, understand and demonstrate awareness of the work * Those without vision and hearing problems * Those without communication problems * Those who volunteered to participate in the study Exclusion Criteria: * Metastatic breast cancer or a history of other cancers * Cancer recurrence detected during the study * Those diagnosed with lymphodema * Patients with bilateral lymph node dissection * Pregnant or breastfeeding patients * Previously participated in a similar training program * Those with a medical condition that prevents them from performing the exercises designed to prevent lymphedema * Patients who refused to participate in the study * Reluctance to continue with the intervention

Inclusion Criteria: * Confirmed diagnosis of HR-positive HER2-negative breast cancer with evidence of locally advanced or metastatic disease, which is not amenable to surgical resection or radiation therapy with curative intent. * Prior CDK4/6 inhibitor therapy in combination with endocrine therapy in advance metastatic setting or in adjuvant setting with documented progression during or within 12 months after the last dose of CDK4/6i. * Participants are eligible if they previously received CDK4/6i or ET as a monotherapy, or in combination for rechallenge therapy in the advance or metastatic setting; have received prior therapy targeting estrogen receptor 1 (ESR1) or breast cancer gene (BRCA)1/2. * Measurable disease evaluable per Response Evaluation Criterion in Solid Tumors (RECIST) v.1.1 or non-measurable bone-only disease * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1. Exclusion Criteria: * Documented detectable PIK3CA/AKT1/PTEN alterations in tissue * Received greater than two prior lines of systemic therapy in the advance or metastatic setting * Had received any prior chemotherapy, including antibody drug conjugates (ADCs), in advance or metastatic setting. Participants who have previously received chemotherapy in the (neo)adjuvant setting are not excluded from the study. * Any medical or psychiatric condition that may increase the risk of study participation or make the participant inappropriate for the study. * Renal impairment, hepatic dysfunction, or hematologic abnormalities.

Inclusion Criteria: * Clinical diagnosis of Type 2 Diabetes mellitus Disease * Must be able to read and speak Portuguese * Being followed exclusively at the primary health care unit for the disease at the beginning of the study * Not participating in other studies involving diabetes mellitus Exclusion Criteria: * Pregnancy * Physical health problems that prevent the patient from coming to the unit * Hearing impairment that compromises communication * Cognitive problems according to the MMSE cutoff points * History of serious psychiatric disorder recorded in the medical record * Patients not located after three attempts of home visits on different days and times

Inclusion Criteria: * Aerobic capacity (V̇O2max) greater than 120% predicted * Body mass index (BMI) \> 18 and \< 30 kg/m2 * Ability to read and understand English * Currently training and/or competing in endurance sports (i.e. running or cycling) Exclusion Criteria: * Smoking history or currently smoking. Currently smoking is defined as regular use of cigarettes or cannabis at any point in the past year. History of smoking is defined as smoking more than 1 pack year for cigarettes or the equivalent in cannabis use measured as puffs per day / 200 (number of puffs in a pack of cigarettes). * Use of cannabis within the past 30 days or has a smoking history of at least 1 pack year. * Use of vaping devices or e-cigarettes in the past 30 days, or has used them more than 10 times in their lifetime. * History or current symptoms of cardiopulmonary disease (excluding controlled asthma) * Contraindications to exercise testing defined as anything that would prevent exercise under proper and safe conditions (e.g., a problem with the heart or lungs, muscle) * Neuromuscular or musculoskeletal condition

Inclusion Criteria: * Participated previously in our preliminary study (EK 1044/2020) and continued Dupilumab treatment since then. Long-term use of Dupilumab since the preliminary study will be assessed based on patient self-report, as there is currently no clinical test or laboratory parameter available to objectively verify treatment duration. * Signed and dated informed consent has been obtained * Current therapy with Dupilumab Exclusion Criteria: * Pregnancy (as determined by urine ß-HCG test) * Clinically significant abnormal laboratory values and active infection (Tbc, HIV, hepatitis A/B/C) * History of malignancy or immunodeficiency * Chronic obstructive lung disorders (COPD), other obstructive lung disorders (bronchiolitis) * Need for systemic corticosteroid therapy 1 month prior to screening visit * Eosinophilic pneumonia and Churg-Strauss Syndrome * Previous anaphylaxis and contraindications against ASA as outlined in the official prescribing information.

Inclusion Criteria: 1. Screen positive women 2. Age 18 - 30 y 3. Gestational Age 11 - 13+6 weeks 4. Singleton Pregnancy 5. Estimated risk for preterm PE of \> 1 in 100 (Reference - Fetal Medicine Foundation) Exclusion Criteria: 1. Screen negative women 2. Age \> 30 y 3. Gestational Age \> 14 weeks 4. Multiple Gestation 5. Estimated risk for preterm PE of \< 1 in 100 (Reference - Fetal Medicine Foundation)

Inclusion Criteria: * Female, over 18 years, have suffered breast cancer, have ended active treatments (chemotherapy, radiotherapy, surgery), have pain or functional limitation or lymphedema at upper limb afected. Exclusion Criteria: * males, people with active treatments ongoning, other types of cancer, recurrence or metastasis of cancer

Inclusion Criteria: * Patients aged 18-90 years * No prior formal diagnosis of HF (including systolic and diastolic dysfunction), PH, or VHD * Ability to provide informed consent Exclusion Criteria: * Severe arrhythmia or unstable cardiovascular disease * Prior formal diagnosis of HF (including systolic and diastolic dysfunction), PH, or VHD * Cardiac implantable electronic device in-situ, including a permanent pacemaker or implantable cardioverter defibrillator * Involvement in current research or recent involvement in any research prior to recruitment

Inclusion Criteria: * Age \> 18 years, \< 80 years * Patients with primary surgical treatment * Postoperative pathology confirmed intrahepatic cholangiocarcinoma * Postoperative pathology showing narrow resection margin (\<1cm) or positive lymph nodes * R0/R1 resection * Postoperative Child-Pugh score A5-B7 * Patients meeting either of the following conditions must undergo preoperative or pre-radiotherapy PET-CT to exclude distant metastasis or lymph node metastasis beyond the region from the lower esophagus to the aortic bifurcation 1. Lymph node metastasis accounting for \>50% of dissected nodes 2. Lymph node metastasis involving the paracardial region or below the renal vein level * Postoperative contrast-enhanced liver MRI to exclude Intrahepatic satellite nodules * Recovery from surgery with Eastern Cooperative Oncology Group performance status score of 0-2 * Estimated life expectancy \>3 months Exclusion Criteria: * History of malignancies, except for basal cell skin carcinoma and in situ carcinoma of the cervix * Had prior abdominal irradiation * Had prior liver transplantation * Had serious myocardial disease or renal failure * Had moderate or severe ascites with obvious symptoms 4 months after surgery * Duration from surgery ≥ 4 months